4-isopropyloxy-2-nitroaniline | 151598-68-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-isopropyloxy-2-nitroaniline
• 英文别名: 4-Isopropoxy-2-nitroaniline；2-nitro-4-propan-2-yloxyaniline
• CAS: 151598-68-4
• 化学式: C₉H₁₂N₂O₃
• 分子量: 196.206
• InChiKey: NWCMJKUTABMPFR-UHFFFAOYSA-N

物化性质

• 沸点：
  348.0±22.0 °C(Predicted)
• 密度：
  1.219±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  81.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-isopropyloxy-2-nitroaniline 在 盐酸 、 sodium acetate 、 sodium hydroxide 、 sodium nitrite 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 生成
  参考文献：
  名称：

  Structure-based design and biological evaluation of novel 2-(indol-2-yl) thiazole derivatives as xanthine oxidase inhibitors

  摘要：

  Inhibition of xanthine oxidase (XO) has obviously been a central concept for controlling hyperuricemia, which causes serious and painful inflammatory arthritis disease such as gout. We discovered a series of novel 2-(indol-2-yl) thiazole derivatives as XO inhibitors at the level of nanomolar activity. Structure-guided design using molecular modeling program (Accelrys Software program) provided an excellent basis for optimization of 2-(indol-2-yl) thiazole compounds. Structure-activity relationship indicated that hydrophobic alkoxy group (isopropoxy, cyclopentoxy) at 5-position and hydrogen binding acceptor (NO2, CN) at 7-position of indole ring appear as critical functional groups. Among the compounds, 2-(7-nitro-5-isopropoxy- indol-2-yl)-4-methylthiazole-5-carboxylic acid (9m) exhibits the most potent XO inhibitory activity (IC50 value: 5.1 nM) and the excellent uric acid lowering activity in potassium oxonate induced hyperuricemic rat model. (C) 2016 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2015.12.055
• 作为产物：
  描述：

  O-异丙基乙酰氨基苯 在 氢氧化钾 、 硝酸 、 溶剂黄146 作用下， 以 甲醇 、 水 为溶剂， 反应 24.25h， 生成 4-isopropyloxy-2-nitroaniline
  参考文献：
  名称：

  Mehta, Lina K.; Parrick, John; Payne, Fereshteh, Journal of the Chemical Society. Perkin transactions I, 1993, # 11, p. 1261 - 1268

  摘要：

  DOI：

文献信息

• Design of a Practical Fluorescent Probe for Superoxide Based on Protection–Deprotection Chemistry of Fluoresceins with Benzenesulfonyl Protecting Groups
  作者：Hatsuo Maeda、Kayoko Yamamoto、Iho Kohno、Leila Hafsi、Norio Itoh、Shinsaku Nakagawa、Naoko Kanagawa、Keiichiro Suzuki、Tadayuki Uno

  DOI：10.1002/chem.200600522

  日期：2007.2.23

  for designing probes based on protection-deprotection chemistry involving fluoresceins and their benzenesulfonyl (BES) derivatives has led to the development of a much more practical superoxide (O(2) (-.)) probe than the previously reported bis(2,4-dinitro-BES) tetrafluorofluorescein (6 a). Examination of various BES derivatives, developed from the starting point of the prototype probe 6 a, yielded

  一种基于荧光-荧光素及其苯磺酰基（BES）衍生物的基于保护-脱保护化学的探针设计策略，已导致比以前报道的bis（2，2）更实用的超氧化物（O（2）（-。））探针的开发。 4-二硝基-BES）四氟荧光素（6a）。从原型探针6a的起点开发的各种BES衍生物的检测产生了作为最佳试剂的4,5-二甲氧基-2-硝基-BES四氟荧光素（BESSo; 7 j）。与基于6 a的分析相比，使用BESSo的微量滴定板分析显示O（2）（-。）的检测极限提高了十倍。BESSo对O（2）（-。）的特异性明显优于对GSH或其他活性氧的特异性，并且该特异性明显高于Fe（2+）和某些还原酶。这些功能已导致开发了一种基于BESSo的测定方法，与基于HPLC的测定方法相比，该方法能够为嗜中性粒细胞释放O（2）（-。）提供更明确的结果，而无论是否受佛波肉豆蔻酸酯乙酸盐的刺激。 6个 通过使用流式细胞仪和荧光显微镜，利用BESSo
• HEPATITIS C VIRUS INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150376233A1

  公开（公告）日：2015-12-31

  Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

  揭示了具有一般式（I）的丙型肝炎病毒抑制剂。还公开了包含这些化合物的组合物和使用这些化合物抑制HCV的方法。
• 9-METHYL SUBSTITUTED HEXADECAHYDROCYCLOPROPA(E)PYRROLO(1,2-A)(1,4)DIAZACYCLOPENTADECINYL CARBAMATE DERIVATIVES AS NON-STRUCTURAL 3 (NS3) PROTEASE INHIBITORS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS
  申请人：Bristol-Myers Squibb Company

  公开号：EP2909205B1

  公开（公告）日：2016-11-23
• EP2909205A1
  申请人：——

  公开号：EP2909205A1

  公开（公告）日：2015-08-26
• PHARMACEUTICAL COMPOSITION COMPRISING SUBSTANCE INHIBITING ENZYMATIC ACTIVITY OF PEROXIREDOXIN 2 AS EFFECTIVE INGREDIENT FOR TREATMENT OF COLORECTAL CANCER
  申请人：EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION

  公开号：US20200129508A1

  公开（公告）日：2020-04-30

  The present invention relates to a pharmaceutical composition for treating colorectal cancer including a material inhibiting the enzyme activity of peroxiredoxin 2 as an active ingredient, and more specifically, to a pharmaceutical composition for treating colorectal cancer, which exhibits the effect of reducing colon polyps via increase of active β-catenin degradation by inhibiting the activity of peroxiredoxin 2, based on the mechanism that promotes colorectal tumor by the interaction between peroxiredoxin 2 (PrxII) and tankyrase (TNKS) in an APC-mutant cell.